Your browser doesn't support javascript.
loading
Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil
Monnerat, Bruno Zanotelli; Cerutti Junior, Crispim; Caniçali, Sheila Cristina; Motta, Tânia Reuter.
  • Monnerat, Bruno Zanotelli; Hospital Universitário Cassiano Antonio de Morais. Infectious Diseases Division.
  • Cerutti Junior, Crispim; Hospital Universitário Cassiano Antonio de Morais. Infectious Diseases Division.
  • Caniçali, Sheila Cristina; Hospital Universitário Cassiano Antonio de Morais. Infectious Diseases Division.
  • Motta, Tânia Reuter; Hospital Universitário Cassiano Antonio de Morais. Infectious Diseases Division.
Braz. j. infect. dis ; 12(4): 364-368, Aug. 2008. tab
Artículo en Inglés | LILACS | ID: lil-496762
ABSTRACT
We designed a retrospective cohort study to identify factors associated with HIV-1 related lipodystrophy at a tertiary HIV-care center in Vitória, ES, Brazil. Inclusion criteria were documented HIV diagnosis, anti-retroviral therapy and age above 17 years. Highly active antiretroviral therapy (HAART) was initially the exposure variable, but a second analysis was also performed, as a nested case-control, based on the presence or absence of lipodystrophy. Use of protease inhibitors (PI) was associated with an increase in serum triglycerides (243.7 ± 189 mg/dL vs. 172.7 ± 131 mg/dL, p = 0.015), but not of total cholesterol (TC) or HDL fraction levels. Non-nucleoside reverse transcriptase inhibitors (NNRTI) were associated with an increase in serum TC (180.6 ± 46.8 mg/dL versus 162.4 ± 41.4 mg/dL; p= 0.018) and an increase in HDL cholesterol (47.3 ± 13.8 mg/dL versus 23.3 ± 24.3 mg/dL; p < 0.001), with no significant effect on triglyceride levels. Lipodystrophy was diagnosed in 59.3 percent of the patients, but exposure to PI versus NNRTI did not affect the frequency of this disorder (43.4 percent versus 37.2 percent; p = 0.68). Serum TC, but not HDL cholesterol or triglyceride levels, was higher among the lipodystrophy cases (183.8 ±47.5 mg/dL versus 162.1 ±35.7; p=0.006). Among the controls (patients without lipodystrophy), HDL cholesterol (45.3 ±14.4 mg/dL vs. 27.1 ±26.3; p=0.001)and triglyceride levels (178.3 ±146.3 mg/dL vs. 126.3 ±126.9; p=0.013) also increased, but not TC. In conclusion, lipodystrophy was highly prevalent in our series. Lipid disorders were also frequent and apparently were related to lipodystrophy, except for triglyceride levels.
Asunto(s)

Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Terapia Antirretroviral Altamente Activa / Síndrome de Lipodistrofia Asociada a VIH / Dislipidemias / Hiperglucemia Tipo de estudio: Estudio diagnóstico / Estudio de etiología / Estudio de incidencia / Estudio observacional / Estudio pronóstico / Factores de riesgo Límite: Adulto / Femenino / Humanos / Masculino País/Región como asunto: America del Sur / Brasil Idioma: Inglés Revista: Braz. j. infect. dis Asunto de la revista: Enfermedades Transmisibles Año: 2008 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Terapia Antirretroviral Altamente Activa / Síndrome de Lipodistrofia Asociada a VIH / Dislipidemias / Hiperglucemia Tipo de estudio: Estudio diagnóstico / Estudio de etiología / Estudio de incidencia / Estudio observacional / Estudio pronóstico / Factores de riesgo Límite: Adulto / Femenino / Humanos / Masculino País/Región como asunto: America del Sur / Brasil Idioma: Inglés Revista: Braz. j. infect. dis Asunto de la revista: Enfermedades Transmisibles Año: 2008 Tipo del documento: Artículo